Pemigatinib price

In patients with advanced cholangiocarcinoma (CCA), gemcitabine/cisplatin combination is the standard first-line chemotherapy, with 5-fluorouracil-based regimens reserved for subsequent treatment; however, expected survival rates are low. Pemigatinib is approved for locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. Pemetinib had a manageable safety profile and achieved durable responses.

Patients with unresectable cholangiocarcinoma often experience high symptom burden and treatment-related toxicities that impact their physical functioning and emotional well-being. Since treatment is primarily aimed at relieving symptoms, controlling symptom burden and improving quality of life should be the main goals of later treatment. In all cases, pemetinib resulted in durable symptomatic improvement, even when radiographic assessment showed stable disease. Benefit duration ranges from6 months to 14 months.

The original drug of pemetinib has been launched in China under the trade name Dabotan. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 9mg*14 tablets may be around 50,000 yuan, which is expensive. The original drug Pemetinib currently on the market overseas, with a specification of 13.5mg*14 tablets, may cost around RMB 70,000 per box (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold abroad. For example, the price of 4.5mg*14 tablets per box produced by a Laos pharmaceutical factory may be around 1,000 yuan (the price may fluctuate due to exchange rates).